STOCK TITAN

If You Invested in Viridian Therapeutics, Inc. (VRDN)

Healthcare · Biotechnology · NASDAQ
Looking for the current price? See the VRDN quote & overview
$1,000 invested 1 Year Ago
$1,067
+6.7% price return
+6.7% with dividends reinvested
Bought on Nov 20, 2025 at $29.47 split-adjusted
$1,000 invested 5 Years Ago
$1,602
+60.2% price return 9.9% CAGR
+60.2% with dividends reinvested
Bought on Nov 22, 2021 at $19.62 split-adjusted

What $1,000 or $10,000 in VRDN Would Be Worth Now

Real historical value by amount invested and how long ago
If you invested 1 year ago 5 years ago 10 years ago Since Nov 23, 2015
$1,000 $1,067 +7% $1,602 +60% $223 -78% $154 -85%
$10,000 $10,668 +7% $16,024 +60% $2,235 -78% $1,536 -85%

Based on real historical closing prices adjusted for stock splits, without dividends, through 2026-11-19. Figures with dividends reinvest each cash dividend at the previous close less the dividend, before taxes. Past performance does not guarantee future results.

Custom Calculation

Choose your own date and amount for VRDN

$1,000 Investment Over Time

VRDN vs S&P 500

Year-by-Year Returns

VRDN annual performance
Year Start Price End Price Annual Return Cumulative
2015Nov 23 to Dec 31 $204.75 $168.30 -17.8% -17.8%
2016 $168.30 $75.15 -55.3% -63.3%
2017 $75.15 $156.45 +108.2% -23.6%
2018 $156.45 $45.45 -70.9% -77.8%
2019 $45.45 $7.20 -84.2% -96.5%
2020 $7.20 $16.45 +128.5% -92.0%
2021 $16.45 $19.77 +20.2% -90.3%
2022 $19.77 $29.21 +47.7% -85.7%
2023 $29.21 $21.78 -25.4% -89.4%
2024 $21.78 $19.17 -12.0% -90.6%
2025 $19.17 $31.12 +62.3% -84.8%
2026Dec 31, 2025 to Nov 19 $31.12 $31.44 +1.0% -84.6%

About Viridian Therapeutics, Inc.

Healthcare · NASDAQ

Viridian Therapeutics, Inc. (Nasdaq: VRDN) is a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for patients with serious and rare diseases. According to company disclosures, Viridian applies its expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates directed at previously validated drug targets in commercially established disease areas. The company is based in Waltham, Massachusetts and its common stock trades on The Nasdaq Stock Market LLC under the symbol VRDN.

Viridian’s lead area of focus is thyroid eye disease (TED), a rare autoimmune disorder affecting the tissues around the eyes. The company is advancing multiple anti–insulin-like growth factor-1 receptor (IGF‑1R) candidates in the clinic for TED across both active and chronic forms of the disease. Its pivotal TED program centers on veligrotug (also referred to as VRDN‑001), an intravenously delivered, anti‑IGF‑1R monoclonal antibody in late-stage development. Viridian has conducted two global phase 3 clinical trials, THRIVE and THRIVE‑2, designed to evaluate veligrotug’s efficacy and safety in patients with active and chronic TED, respectively. Company reports state that both trials met their primary and all secondary endpoints and showed a rapid onset of clinical benefit, including statistically significant and clinically meaningful effects on measures such as proptosis and diplopia, with veligrotug generally well tolerated.

Building on the veligrotug program, Viridian is also developing elegrobart (VRDN‑003), a subcutaneously delivered, half‑life extended anti‑IGF‑1R antibody. VRDN‑003 shares the same binding domain as veligrotug and has been engineered for a longer half‑life. It is being studied as a potential subcutaneous therapy for TED in two global phase 3 pivotal trials, REVEAL‑1 and REVEAL‑2, which evaluate dosing every four weeks and every eight weeks in patients with active and chronic TED. Company materials describe VRDN‑003 as designed for administration via a low‑volume autoinjector that patients could self‑administer at home, with dosing regimens intended to align with exposure levels associated with clinical activity observed for veligrotug in earlier studies.

Beyond IGF‑1R inhibition, Viridian is expanding its TED-focused pipeline with an anti–thyroid‑stimulating hormone receptor (TSHR) program. The company describes this program as a half‑life extended monoclonal antibody that inhibits TSHR and is designed for subcutaneous delivery in an autoinjector with extended dosing intervals. The TSHR program is being advanced as a potential therapy for TED or Graves disease, reflecting Viridian’s strategy of addressing multiple biologic drivers implicated in thyroid-related autoimmune conditions.

Viridian is also developing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors with potential application across multiple autoimmune diseases. This portfolio includes VRDN‑006, described as a highly selective Fc fragment that inhibits FcRn and is designed as a convenient subcutaneous, self‑administered option. In a phase 1 healthy volunteer trial, VRDN‑006 demonstrated proof‑of‑concept reductions in immunoglobulin G (IgG) consistent with the FcRn inhibitor class and was reported to spare albumin and low‑density lipoprotein (LDL), with the program described as generally well tolerated. Viridian’s second FcRn candidate, VRDN‑008, is characterized as a bi‑specific, half‑life extended FcRn inhibitor that combines an Fc fragment with an albumin‑binding domain. Preclinical data in non‑human primates disclosed by the company indicate that VRDN‑008 showed a longer half‑life and more sustained IgG reduction than efgartigimod after a single high‑dose head‑to‑head study.

Across these programs, Viridian emphasizes a development strategy that targets serious and rare conditions where validated biological pathways already exist, and where the company believes differentiated antibody engineering can yield therapeutic profiles that may be attractive to patients, physicians, and payers. In TED, Viridian’s clinical and regulatory efforts include late-stage intravenous and subcutaneous candidates, as well as plans for geographic expansion through regulatory submissions such as a Marketing Authorization Application to the European Medicines Agency, as described in company press releases. In addition, Viridian has entered into a collaboration and license agreement with Kissei Pharmaceutical Co., Ltd., granting Kissei an exclusive license to develop and commercialize products containing veligrotug and VRDN‑003 in Japan, with Viridian retaining manufacturing responsibilities for those products under specified circumstances and being eligible for upfront, milestone, and royalty payments.

Viridian’s disclosures also describe steps toward building commercial capabilities around its TED portfolio, including preparations for a potential U.S. launch of veligrotug and subsequent commercialization of VRDN‑003, subject to regulatory approvals. The company has discussed assembling leadership in areas such as sales, market access, patient services, and medical affairs, and focusing on a defined group of physicians who are key prescribers in the TED treatment landscape. Financing transactions, including public equity offerings, royalty financing agreements, and credit facilities, have been highlighted by Viridian as mechanisms to support its clinical programs and anticipated commercialization activities.

Overall, Viridian Therapeutics presents itself as a clinical-stage biopharmaceutical company with a concentrated focus on antibody-based therapies for serious and rare diseases, particularly thyroid eye disease and autoimmune conditions where modulation of IGF‑1R, TSHR, or FcRn pathways may provide clinical benefit. The company’s pipeline spans late-stage pivotal trials in TED and earlier-stage FcRn inhibitor programs, all underpinned by its stated capabilities in antibody discovery and protein engineering.

Business focus and therapeutic areas

According to Viridian’s public statements, the company’s core business focus includes:

  • Thyroid eye disease (TED): Development of intravenous and subcutaneous anti‑IGF‑1R antibodies (veligrotug and VRDN‑003/elegrobart) in global phase 3 clinical programs, and advancement of an anti‑TSHR monoclonal antibody program as a potential therapy for TED or Graves disease.
  • Autoimmune diseases: Advancement of a portfolio of FcRn inhibitors (VRDN‑006 and VRDN‑008) with potential application in multiple autoimmune conditions, supported by early clinical and preclinical data on IgG reduction and pharmacokinetic properties.
  • Antibody engineering: Use of antibody discovery and protein engineering expertise to generate differentiated candidates for validated targets, with an emphasis on half‑life extension, route of administration (intravenous vs. subcutaneous), and dosing schedules designed for patient convenience.

Regulatory and clinical development context

Viridian has reported several notable regulatory and clinical milestones for its TED programs. The company has stated that veligrotug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for TED, and that the FDA accepted a Biologics License Application (BLA) for veligrotug with Priority Review and a Prescription Drug User Fee Act (PDUFA) target action date. The BLA is supported by data from the THRIVE and THRIVE‑2 phase 3 trials, which, according to Viridian, met all primary and secondary endpoints and demonstrated rapid onset of clinical benefit, including improvements in proptosis and diplopia, with veligrotug generally well tolerated.

For VRDN‑003/elegrobart, Viridian has described two ongoing global phase 3 pivotal clinical trials, REVEAL‑1 and REVEAL‑2, in active and chronic TED, respectively, assessing subcutaneous dosing every four or eight weeks. Company communications note that enrollment targets in these studies were exceeded, driven by what Viridian characterizes as strong patient demand, and that topline data readouts are planned on a defined timeline.

Collaborations and geographic reach

Viridian’s collaboration with Kissei Pharmaceutical Co., Ltd., as disclosed in an 8‑K filing, grants Kissei an exclusive license to develop and commercialize veligrotug and VRDN‑003 in Japan, including for potential treatment of TED. Under this agreement, Kissei is responsible for development and regulatory activities in Japan, while Viridian maintains certain manufacturing responsibilities and is eligible for upfront, milestone, and tiered royalty payments based on net sales in that territory. This collaboration illustrates Viridian’s approach to expanding the reach of its TED therapies beyond the United States through regional partnerships.

Stock listing and corporate governance

Viridian Therapeutics’ common stock is registered under Section 12(b) of the Securities Exchange Act of 1934 and trades on The Nasdaq Stock Market LLC under the ticker symbol VRDN, as noted in multiple Form 8‑K filings. The company has an Amended and Restated 2016 Equity Incentive Plan and has disclosed shareholder approvals of amendments to increase the number of shares available for issuance under that plan, as well as the adoption of an employee stock purchase plan. Viridian also reports periodic inducement grants of stock options to new employees under Nasdaq Listing Rule 5635(c)(4), reflecting the use of equity-based compensation as part of its talent strategy.

Market Cap
$3.6B
Current Price
$31.44
Revenue (FY2025)
$70.8M
View full VRDN overview

Frequently Asked Questions

Viridian Therapeutics, Inc. investment returns

How much would $1,000 invested in Viridian Therapeutics, Inc. be worth today?

If you invested $1,000 in Viridian Therapeutics, Inc. (VRDN) 10 years ago on 2016-11-21, your investment would be worth $223 as of 2026-11-19, a -77.7% price return without dividends, growing at a compounded rate of -13.9% per year (CAGR).

Has Viridian Therapeutics, Inc. outperformed the S&P 500?

Over the past 10 years, VRDN returned -77.7% compared to +225.2% for the S&P 500, underperforming the benchmark by 302.8 percentage points.

What is Viridian Therapeutics, Inc.'s average annual return?

The compound annual growth rate (CAGR) of VRDN’s share price over the past 10 years is -13.9%, without dividends. Individual years vary a great deal, and VRDN’s best recent full year was 2020 (+128.5%) while the worst was 2019 (-84.2%).

For informational and educational purposes only, not investment advice.